샘플 요청 목록

 카트 문의
시장보고서
상품코드
1777378

심장학 및 신경학 IVD 시장

IVD in Cardiology and Neurology
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 378 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 심장학 및 신경학 IVD 시장은 2030년까지 278억 달러에 이를 전망

2024년에 173억 달러로 추정되는 심장학 및 신경학 IVD 세계 시장은 2024-2030년간 CAGR 8.2%로 성장하여 2030년에는 278억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 기구는 CAGR 9.8%를 나타내고, 분석 기간 종료까지 170억 달러에 이를 것으로 예측됩니다. 시약 및 소모품 부문의 성장률은 분석 기간중 CAGR 5.8%로 추정됩니다.

미국 시장은 추정 47억 달러, 중국은 CAGR13.1%로 성장 예측

미국의 심장학 및 신경학 IVD 시장은 2024년에 47억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 61억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 13.1%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 4.0%와 8.0%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 5.5%를 나타낼 전망입니다.

심장학 및 신경학 IVD 시장 - 주요 동향과 촉진요인 정리

심장학 및 신경학 분야의 체외진단(IVD)은 빠르게 발전하고 있으며, 질병의 조기 발견, 위험성 평가, 맞춤 치료 전략을 가능하게 하고 있습니다. 심혈관 질환과 신경 질환은 전 세계적으로 사망률과 장애의 주요 원인으로, IVD 기술은 환자의 예후 개선에 중요한 역할을 하고 있습니다. 바이오마커 기반 검사, 분자진단, 현장진단(POC) 검사, 디지털 헬스 통합의 발전은 이 분야의 기술 혁신을 촉진하고 있습니다.

심장병, 뇌졸중, 신경 퇴행성 질환, 인지 장애의 유병률이 증가함에 따라 의료진과 연구자들은 정확한 진단, 질병 모니터링, 치료 최적화를 위해 IVD 솔루션에 대한 의존도가 높아지고 있습니다. 고감도 심장 및 신경 바이오마커, AI 기반 진단, 신속 검사 솔루션에 대한 수요가 시장 성장을 가속하고 임상적 의사결정을 변화시키고 있습니다.

기술 발전은 심장학 체외진단 의약품을 어떻게 향상시키고 있는가?

심장 체외 진단 분야, 특히 고감도 분석, 현장 진료 심장 바이오마커 검사, 분자진단 분야에서 획기적인 발전이 이루어지고 있습니다. 가장 중요한 혁신 중 하나는 심근경색(MI)과 급성관상동맥증후군(ACS)을 조기에 발견할 수 있는 고감도 심근 트로포닌(hs-cTn) 검사의 개발입니다. 이 초민감성 분석은 심근 트로포닌 수치의 미세한 변화를 감지하여 조기 개입, 위험 계층화 개선, 입원율 감소를 가능하게 합니다.

또 다른 큰 발전은 심혈관 질환 위험 평가를 위한 다중 바이오마커 패널의 통합입니다. 기존에는 지질 프로파일(LDL, HDL, 총콜레스테롤, 중성지방)이 심혈관 건강 상태를 평가하는 기준이었습니다. 그러나 최신 IVD 솔루션은 고감도 CRP(hs-CRP), 나트륨 이뇨 펩타이드(BNP/NT-proBNP), 미엘로퍼옥시다아제(MPO)와 같은 바이오마커를 통합하여 종합적인 심혈관 위험에 대한 통찰력을 제공합니다. 이러한 첨단 바이오마커 측정은 개인화된 예방 전략과 조기 심혈관 질환(CVD) 개입을 가능하게 합니다.

심장 마커에 대한 현장진단(POC) 검사의 확대도 중요한 추세입니다. 휴대용, 신속, 핸드헬드 POC 분석기를 통해 현재 응급실, 구급차, 1차 진료 현장에서 실시간으로 트로포닌, D-dimer, BNP를 검사할 수 있습니다. 이를 통해 조기 분류 판단이 크게 개선되고, 소요 시간이 단축되며, 병원 전 심장 사건 관리가 강화되었습니다. 또한, 웨어러블 바이오센서 및 원격 심장 모니터링 기기의 등장으로 지속적인 심장 건강 상태를 추적할 수 있게 되어 적극적인 개입과 심부전 및 부정맥으로 인한 입원을 줄일 수 있게 되었습니다.

또한, 유전성 심혈관계 질환에 대한 분자 및 유전자 검사는 질환의 예방과 관리에 변화를 가져오고 있습니다. 가족성 고콜레스테롤혈증(FH), 비후성 심근증(HCM), QT 연장 증후군(LQTS)과 같은 질환에 대한 유전자 검사가 보다 쉽게 이용할 수 있게 되어 위험에 처한 개인을 조기에 발견하고 생활습관 및 약리학적 개입을 목표로 삼을 수 있게 되었습니다. AI를 통한 심전도 해석과 디지털 병리학의 통합도 CVD의 자동 진단과 예후 예측을 진행하고 있습니다.

신경 분야 IVD를 주도하는 시장 동향은?

신경진단 분야는 신경퇴행성 질환, 뇌졸중, 인지장애에 대한 부담 증가에 힘입어 급속한 변화를 겪고 있습니다. 가장 중요한 트렌드 중 하나는 알츠하이머병(AD)과 파킨슨병(PD)에 대한 혈액 기반 바이오마커의 개발입니다. 기존에는 알츠하이머병 진단을 위해 뇌척수액(CSF) 분석이나 PET 영상진단에 의존해 왔으나, 두 가지 모두 침습적이고 비용이 많이 듭니다. 그러나 최근 β& 아밀로이드(Aβ&42/Aβ&40 비율), 타우 단백질(pTau-181, pTau-217), 뉴로필라멘트 경쇄(NfL)에 대한 혈장 기반 분석이 발전하여 알츠하이머병 및 기타 신경 퇴행성 질환에 대한 비 비침습적이고 확장 가능한 스크리닝이 가능해졌습니다.

또 다른 큰 흐름은 신경학에서의 분자진단, 특히 신경발달장애, 간질, 신경근육질환에 대한 유전자 검사가 확대되고 있다는 점입니다. 차세대 염기서열분석기(NGS)와 크리스퍼(CRISPR)를 이용한 진단법의 발전으로 근위축성 측색경화증(ALS), 다발성 경화증(MS), 유전성 실조증과 같은 질병과 관련된 유전자 변이를 조기에 발견할 수 있게 되었습니다. 이러한 정밀 진단 도구는 개인 맞춤형 치료 선택, 조기 개입, 표적 유전자 치료를 촉진합니다.

뇌졸중 진단 및 관리를 위한 IVD 솔루션의 부상도 시장 성장의 원동력이 되고 있습니다. 기존에는 뇌졸중 진단이 신경영상(CT, MRI)에 의존해 왔으나, 신경섬유산성단백질(GFAP), S100B, D다이머 등 뇌졸중 바이오마커 패널의 도입으로 뇌졸중의 조기발견과 허혈성 뇌졸중과 출혈성 뇌졸중의 감별이 강화되고 있습니다. POC 혈액 기반 뇌졸중 검사는 병원 전 뇌졸중 평가의 게임 체인저로 부상하고 있으며, 신속한 개입과 환자 예후 개선을 가능하게 합니다.

또한, AI를 활용한 신경 진단, 디지털 바이오마커, 원격 모니터링의 통합이 진행되어 신경 질환의 발견과 진행 추적을 혁신적으로 변화시키고 있습니다. 뇌파, MRI, 음성 패턴의 AI를 활용한 분석으로 간질, 치매, 운동장애 진단이 개선되고 있으며, 웨어러블 신경기술로 파킨슨병, MS, 뇌졸중 후 재활을 위한 실시간 신경 모니터링이 가능해졌습니다.

심장학 및 신경학에서 IVD의 성장 원동력은 무엇인가?

심혈관 및 신경계 IVD 시장은 심혈관 및 신경 퇴행성 질환의 유병률 증가, 바이오마커 탐색의 발전, 비침습적 진단에 대한 수요 증가 등 몇 가지 주요 성장 촉진요인에 의해 확대되고 있습니다. 가장 중요한 성장 요인 중 하나는 CVD와 뇌졸중으로 인한 세계 부담이며, 이는 여전히 전 세계 사망 원인 중 가장 높은 비중을 차지하고 있습니다. 헬스케어 시스템이 조기 발견, 예방, 개인 맞춤형 치료 접근법에 초점을 맞추면서 고감도 심장 바이오마커와 신속 뇌졸중 진단에 대한 수요가 가속화되고 있습니다.

또한, 알츠하이머병, 파킨슨병 등 신경퇴행성 질환의 발병률 증가의 원인이 되고 있는 인구 고령화도 중요한 원동력이 되고 있습니다. 조기 발견과 개입이 우선시되는 가운데, 혈액 기반 바이오마커, 유전자 스크리닝, AI를 활용한 신경영상 분석에 기반한 IVD 솔루션이 각광받고 있습니다.

또한, 현장 진료(POC) 검사 및 분산형 진단의 채택이 증가하고 있는 것도 시장 성장을 가속하고 있습니다. 병원 기반 실험실 검사에서 휴대용 및 신속한 진단 솔루션으로의 전환은 신속한 의사 결정, 환자 분류 개선, 급성 심장 및 신경 질환의 더 나은 관리를 가능하게 하고 있습니다. 응급의료, 1차의료, 재택진단이 확대됨에 따라 IVD 제조업체들은 작고 사용하기 쉽고 민감도가 높은 현장진단(POC) 검사 플랫폼에 투자하고 있습니다.

IVD 중심의 정밀의료에 대한 규제와 상환 지원도 시장 성장에 영향을 미치는 주요 요인입니다. 정부와 의료 기관은 환자의 결과를 최적화하고 의료비를 절감하기 위해 바이오마커 중심의 치료 전략, 유전성 질환의 유전자 검사, AI 통합 진단을 추진하고 있습니다. 또한, 디지털 헬스 기술 및 원격 환자 모니터링에 대한 투자가 증가하면서 AI를 활용한 심장 및 신경 진단의 기술 혁신을 촉진하고 있습니다.

부문

제품 유형(장비, 시약 및 소모품, 소프트웨어 및 서비스), 기술(면역측정, 분자진단, 혈액학, 기타), 최종사용자(병원, 임상 실험실, 기타)

조사 대상 기업 예

  • Abbott Laboratories
  • Agilent Technologies
  • AliveCor
  • Becton, Dickinson and Company(BD)
  • bioMerieux S.A.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Hologic Inc.
  • LivaNova
  • Medtronic
  • Mindray Medical International Limited
  • Ortho Clinical Diagnostics
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Roche Diagnostics
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계 고유 SLM를 쿼리 하는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.04

Global IVD in Cardiology and Neurology Market to Reach US$27.8 Billion by 2030

The global market for IVD in Cardiology and Neurology estimated at US$17.3 Billion in the year 2024, is expected to reach US$27.8 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$17.0 Billion by the end of the analysis period. Growth in the Reagents & Consumables segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.7 Billion While China is Forecast to Grow at 13.1% CAGR

The IVD in Cardiology and Neurology market in the U.S. is estimated at US$4.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.1 Billion by the year 2030 trailing a CAGR of 13.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

IVD in Cardiology and Neurology Market - Key Trends & Drivers Summarized

In-vitro diagnostics (IVD) in cardiology and neurology is rapidly evolving, enabling early disease detection, risk assessment, and personalized treatment strategies. As cardiovascular and neurological disorders continue to be leading causes of mortality and disability worldwide, IVD technologies are playing a crucial role in improving patient outcomes. Advances in biomarker-based testing, molecular diagnostics, point-of-care (POC) testing, and digital health integration are driving innovation in this sector.

With the rising prevalence of heart disease, stroke, neurodegenerative disorders, and cognitive impairments, healthcare providers and researchers are increasingly relying on IVD solutions for accurate diagnosis, disease monitoring, and therapy optimization. The demand for high-sensitivity cardiac and neurological biomarkers, AI-driven diagnostics, and rapid testing solutions is fueling market growth and transforming clinical decision-making.

How Are Technological Advancements Enhancing IVD in Cardiology?

The field of cardiac in-vitro diagnostics has witnessed groundbreaking advancements, particularly in high-sensitivity assays, point-of-care cardiac biomarker testing, and molecular diagnostics. One of the most significant innovations is the development of high-sensitivity cardiac troponin (hs-cTn) tests, which enable the early detection of myocardial infarction (MI) and acute coronary syndrome (ACS). These ultrasensitive assays detect minute changes in cardiac troponin levels, allowing for earlier intervention, improved risk stratification, and reduced hospital admissions.

Another major breakthrough is the integration of multi-biomarker panels for cardiovascular disease risk assessment. Traditionally, lipid profiles (LDL, HDL, total cholesterol, and triglycerides) were the standard for evaluating cardiovascular health. However, modern IVD solutions now incorporate additional biomarkers such as high-sensitivity C-reactive protein (hs-CRP), natriuretic peptides (BNP/NT-proBNP), and myeloperoxidase (MPO) to provide comprehensive cardiovascular risk insights. These advanced biomarker assays are enabling personalized preventive strategies and early-stage cardiovascular disease (CVD) intervention.

The expansion of point-of-care (POC) testing for cardiac markers is another critical trend. Portable, rapid, and handheld POC analyzers now allow for real-time troponin, D-dimer, and BNP testing in emergency rooms, ambulances, and primary care settings. This has significantly improved early triage decisions, reduced turnaround times, and enhanced pre-hospital cardiac event management. Additionally, the rise of wearable biosensors and remote cardiac monitoring devices is enabling continuous cardiac health tracking, leading to proactive interventions and reduced hospitalizations for heart failure and arrhythmias.

Furthermore, molecular and genetic testing for inherited cardiovascular conditions is transforming disease prevention and management. Genetic screening for conditions such as familial hypercholesterolemia (FH), hypertrophic cardiomyopathy (HCM), and long QT syndrome (LQTS) is becoming more accessible, allowing early identification of at-risk individuals and targeted lifestyle or pharmacological interventions. The integration of AI-driven ECG interpretation and digital pathology is also advancing automated CVD diagnosis and prognosis prediction.

What Market Trends Are Driving IVD in Neurology?

The field of neurological diagnostics is undergoing rapid transformation, fueled by the increasing burden of neurodegenerative diseases, stroke, and cognitive disorders. One of the most significant trends is the development of blood-based biomarkers for Alzheimer’s disease (AD) and Parkinson’s disease (PD). Traditionally, the diagnosis of Alzheimer’s relied on cerebrospinal fluid (CSF) analysis or PET imaging, both of which are invasive and expensive. However, recent advancements in plasma-based assays for beta-amyloid (Aβ42/Aβ40 ratio), tau proteins (pTau-181, pTau-217), and neurofilament light chain (NfL) have enabled non-invasive and scalable screening for Alzheimer’s and other neurodegenerative diseases.

Another major trend is the expansion of molecular diagnostics in neurology, particularly in genetic testing for neurodevelopmental disorders, epilepsy, and neuromuscular conditions. Advances in next-generation sequencing (NGS) and CRISPR-based diagnostics are enabling early detection of genetic mutations linked to conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and hereditary ataxias. These precision diagnostic tools are facilitating personalized treatment selection, early interventions, and targeted gene therapies.

The rise of IVD solutions for stroke diagnosis and management is also driving market growth. Traditionally, stroke diagnosis relied on neuroimaging (CT, MRI); however, the introduction of stroke biomarker panels, including glial fibrillary acidic protein (GFAP), S100B, and D-dimer, is enhancing early stroke detection and differentiation between ischemic and hemorrhagic strokes. POC blood-based stroke tests are emerging as a game-changer for pre-hospital stroke assessment, allowing for rapid intervention and better patient outcomes.

Additionally, the growing integration of AI-driven neurodiagnostics, digital biomarkers, and remote monitoring is transforming neurological disease detection and progression tracking. AI-powered analysis of EEG, MRI, and speech patterns is improving the diagnosis of epilepsy, dementia, and movement disorders, while wearable neurotechnology is enabling real-time neuromonitoring for Parkinson’s, MS, and post-stroke rehabilitation.

What Is Driving the Growth of IVD in Cardiology and Neurology?

The IVD market in cardiology and neurology is expanding due to several key growth drivers, including the rising prevalence of cardiovascular and neurodegenerative diseases, advancements in biomarker discovery, and the growing demand for non-invasive diagnostics. One of the most significant growth drivers is the global burden of CVD and stroke, which remain the leading causes of death worldwide. As healthcare systems focus on early detection, prevention, and personalized treatment approaches, the demand for high-sensitivity cardiac biomarkers and rapid stroke diagnostics is accelerating.

Another critical driver is the aging population, which is contributing to the increased incidence of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. With early-stage detection and intervention becoming a priority, IVD solutions based on blood-based biomarkers, genetic screening, and AI-driven neuroimaging analysis are gaining traction.

The increasing adoption of point-of-care (POC) testing and decentralized diagnostics is also fueling market growth. The shift from hospital-based laboratory testing to portable, rapid diagnostic solutions is enabling quicker decision-making, improved patient triage, and better management of acute cardiac and neurological conditions. As emergency medicine, primary care, and home-based diagnostics expand, IVD manufacturers are investing in compact, user-friendly, and highly sensitive POC testing platforms.

Regulatory and reimbursement support for IVD-driven precision medicine is another major factor influencing market growth. Governments and healthcare agencies are promoting biomarker-driven treatment strategies, genetic testing for hereditary conditions, and AI-integrated diagnostics to optimize patient outcomes and reduce healthcare costs. Additionally, the rising investments in digital health technologies and remote patient monitoring are driving innovation in AI-powered cardiac and neurological diagnostics.

SCOPE OF STUDY:

The report analyzes the IVD in Cardiology and Neurology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Instruments, Reagents & Consumables, Software & Services); Technology (Immunoassays, Molecular Diagnostics, Hematology, Others); End-Use (Hospitals, Clinical Laboratories, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Agilent Technologies
  • AliveCor
  • Becton, Dickinson and Company (BD)
  • bioMerieux S.A.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Hologic Inc.
  • LivaNova
  • Medtronic
  • Mindray Medical International Limited
  • Ortho Clinical Diagnostics
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Roche Diagnostics
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • IVD in Cardiology and Neurology - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Cardiovascular and Neurodegenerative Disorders Drives Demand for IVD Biomarkers
    • OEM Focus on Early Diagnosis and Risk Stratification Supports Adoption of Specialized IVD Panels
    • Growing Awareness of Stroke and Heart Attack Prevention Boosts Demand for Rapid Testing in Emergency Settings
    • Expansion of Point-of-Care Testing Capabilities Enhances IVD Use in Pre-Hospital and Critical Care Scenarios
    • Increased Investment in High-Sensitivity Troponin and NT-proBNP Assays Fuels Cardiac Test Innovation
    • OEM Innovation in Multi-Biomarker Panels Enables Comprehensive Cardiometabolic and Neuro Panel Testing
    • Integration of IVD With Imaging and EHR Systems Supports Clinical Decision-Making in Cardiology and Neurology
    • Rising Demand for Cost-Effective Stroke Risk Screening Tools Drives Expansion of Blood-Based Diagnostics
    • Expansion of Telecardiology and Teleneurology Services Fuels Need for Decentralized IVD Testing Platforms
    • Growth in Chronic Care Management Models Supports Regular Monitoring of Cardiac and Neurological Biomarkers
    • OEM Development of At-Home and Wearable IVD Devices Enhances Access to Long-Term Disease Monitoring
    • Aging Global Population and Increased Dementia Screening Drive Market for Alzheimers-Related Biomarkers
    • Rising Use of Genetic and Proteomic Testing in Neurology Drives Integration of IVD in Precision Medicine
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World IVD in Cardiology and Neurology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for IVD in Cardiology and Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Reagents & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Reagents & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Clinical Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Clinical Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • JAPAN
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • CHINA
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • EUROPE
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for IVD in Cardiology and Neurology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • FRANCE
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • GERMANY
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • INDIA
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for IVD in Cardiology and Neurology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for IVD in Cardiology and Neurology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030
  • AFRICA
    • IVD in Cardiology and Neurology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for IVD in Cardiology and Neurology by Product Type - Instruments, Reagents & Consumables and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for IVD in Cardiology and Neurology by Product Type - Percentage Breakdown of Value Sales for Instruments, Reagents & Consumables and Software & Services for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for IVD in Cardiology and Neurology by End-Use - Other End-Uses, Hospitals and Clinical Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for IVD in Cardiology and Neurology by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Clinical Laboratories for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for IVD in Cardiology and Neurology by Technology - Immunoassays, Molecular Diagnostics, Hematology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for IVD in Cardiology and Neurology by Technology - Percentage Breakdown of Value Sales for Immunoassays, Molecular Diagnostics, Hematology and Other Technologies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제